Radius Health (RDUS) withdraws its plans for an initial public offering, citing general market conditions. The biopharmaceutical firm announced plans for an $86M IPO in February, looking to use the proceeds to fund the clinical development of its most advanced product candidates. The IPO was slated to launch in the last week of October, but was pushed back into election week amid the disruption of superstorm Sandy, then rescheduled again as markets fell following the U.S. vote.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs